Big pharma’s role in mental illness

Story from The Takeaway. Listen to audio above for full report.

For almost 40 years, conventional wisdom has been that mental illness is caused by a chemical imbalance in the brain. “Serotonin” is a household word, along with Prozac, Zyprexa and Zoloft.  But recently, there’s been a vigorous debate within the medical community over whether that line of thinking is accurate.

This summer Marcia Angell, a physician, senior lecturer at Harvard, and former editor-in-chief of The New England Journal of Medicine, wrote in the New York Review of Books that the chemical imbalance model of mental illness may be ineffective at best, and harmful at worst. In her article, Angell talked about medical journalist Robert Whitaker’s book “Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America.”

Whitaker researched years of drug trials and determined that pharmaceutical companies play an enormous role in deciding what causes mental illness, who qualifies as mentally ill, and how those illnesses should be treated. “In 1987, which is when Prozac comes to market, there were 1.25 million people on disability in the United State due to mental illness,” he told The Takeaway. “Today, there’s 4 million.”

Read Marcia Angell’s article in the in the New York Review of Books.

————————————————————–

“The Takeaway” is a national morning news program, delivering the news and analysis you need to catch up, start your day, and prepare for what’s ahead. The show is a co-production of WNYC and PRI, in editorial collaboration with the BBC, The New York Times Radio, and WGBH.